Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline hydrochloride extended-release tablets are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. minocycline hydrochloride extended-release tablets did not demonstrate any effect on non-inflammatory acne lesions. safety of minocycline hydrochloride extended-release tablets has not been established beyond 12 weeks of use. this formulation of minocycline has not been evaluated in the treatment of infections [see clinical studies (14) ]. to reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, minocycline hydrochloride extended-release tablets should be used only as indicated [see warnings and precautions (5.11) ]. this drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. [see warnings and precautions (5.1) ]. minocycline hydrochloride extended-release tablets should not be used during pregnancy. if the patient beco

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline hydrochloride extended-release tablets are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. minocycline hydrochloride extended-release tablets did not demonstrate any effect on non-inflammatory acne lesions. safety of minocycline hydrochloride extended-release tablets has not been established beyond 12 weeks of use. this formulation of minocycline has not been evaluated in the treatment of infections [see clinical studies (14) ]. to reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, minocycline hydrochloride extended-release tablets should be used only as indicated [see warnings and precautions (5.11) ]. this drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. teratogenic effects pregnancy category d [see warnings and precautions (5.1) ] minocycline hydrochloride extended-release tablets should not be

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

northstar rx llc - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline hydrochloride extended-release tablets are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. minocycline hydrochloride extended-release tablets did not demonstrate any effect on non-inflammatory acne lesions. safety of minocycline hydrochloride extended-release tablets has not been established beyond 12 weeks of use. this formulation of minocycline has not been evaluated in the treatment of infections [see clinical studies (14)]. to reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, minocycline hydrochloride extended-release tablets should be used only as indicated [see warnings and precautions (5.11)]. this drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. teratogenic effects: pregnancy category d [see warnings and precautions (5.1)] minocycline hydrochloride extended-release tablets should n

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

jg pharma, inc. - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline hydrochloride extended-release capsules is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. to reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, minocycline hydrochloride extended-release capsules should be used only as indicated [see warnings and precautions (5.11)] . minocycline hydrochloride extended-release capsules did not demonstrate any effect on non-inflammatory acne lesions. safety of minocycline hydrochloride extended-release capsules has not been established beyond 12 weeks of use. this formulation of minocycline has not been evaluated in the treatment of infections [see clinical studies (14)] . minocycline hydrochloride extended-release capsules is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines [see adverse reactions (6.2)] . teratogenic effects: pregnancy category d [see warnings and precautions (5.1)] minocycline hydrochloride extended-release capsules should not be used during pregnancy. if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and stop treatment immediately. there are no adequate and well-controlled studies on the use of minocycline in pregnant women. minocycline, like other tetracycline-class drugs, crosses the placenta and can cause fetal harm when administered to a pregnant woman. spontaneous reports of congenital anomalies including limb reduction have been reported with minocycline use in pregnancy in postmarketing experience. only limited information is available regarding these reports; therefore, no conclusion on causal association can be established. minocycline induced skeletal malformations (bent limb bones) in fetuses when administered to pregnant rats and rabbits in doses of 30 mg/kg/day and 100 mg/kg/day, respectively, (resulting in approximately 3 times and 2 times, respectively, the systemic exposure to minocycline observed in patients as a result of use of minocycline hydrochloride extended-release capsules). reduced mean fetal body weight was observed in studies in which minocycline was administered to pregnant rats at a dose of 10 mg/kg/day (which resulted in approximately the same level of systemic exposure to minocycline as that observed in patients who use minocycline hydrochloride extended-release capsules). minocycline was assessed for effects on peri- and post-natal development of rats in a study that involved oral administration to pregnant rats from day 6 of gestation through the period of lactation (postpartum day 20), at dosages of 5, 10, or 50 mg/kg/day. in this study, body weight gain was significantly reduced in pregnant females that received 50 mg/kg/day (resulting in approximately 2.5 times the systemic exposure to minocycline observed in patients as a result of use of minocycline hydrochloride extended-release capsules). no effects of treatment on the duration of the gestation period or the number of live pups born per litter were observed. gross external anomalies observed in f1 pups (offspring of animals that received minocycline) included reduced body size, improperly rotated forelimbs, and reduced size of extremities. no effects were observed on the physical development, behavior, learning ability, or reproduction of f1 pups, and there was no effect on gross appearance of f2 pups (offspring of f1 animals). tetracycline-class antibiotics are excreted in human milk. because of the potential for serious adverse effects on bone and tooth development in nursing infants from the tetracycline-class antibiotics, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother [see warnings and precautions (5.1)] . minocycline hydrochloride extended-release capsules is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years and older. safety and effectiveness in pediatric patients below the age of 12 have not been established. use of tetracycline-class antibiotics below the age of 8 is not recommended due to the potential for tooth discoloration [see warnings and precautions (5.1)] . clinical studies of minocycline hydrochloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

bryant ranch prepack - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline hydrochloride extended-release tablets is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. minocycline hydrochloride extended-release tablets did not demonstrate any effect on non-inflammatory acne lesions. safety of minocycline hydrochloride extended-release tablets has not been established beyond 12 weeks of use. this formulation of minocycline has not been evaluated in the treatment of infections [see clinical studies (14)] . to reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, minocycline hydrochloride extended-release tablets should be used only as indicated [see warnings and precautions (5.11)] . this drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. teratogenic effects: pregnancy category d [see warnings and precautions (5.1)] minocycline hyd

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

unit dose services - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline 100 mg

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

bryant ranch prepack - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline 100 mg

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

kaiser foundation hospitals - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline 100 mg

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

cardinal health - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline 50 mg

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

direct rx - minocycline hydrochloride (unii: 0020414e5u) (minocycline - unii:fyy3r43wgo) - minocycline 100 mg - pantoprazole sodium delayed-release tablets usp are indicated for: 1.1 short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease (gerd) pantoprazole sodium delayed-release tablets usp are indicated in adults for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets usp may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. 1.2 maintenance of healing of erosive esophagitis pantoprazole sodium delayed-release tablets usp are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. 1.3 pathological hypersecretory conditions including zollinger-ellison syndrome pantopra